LLY 13 min read

Eli Lilly and Company (LLY) — Investment Tree v1

Stage 7 final essay. Bilingual companion: tree_v1_zh.md. Date: 2026-05-19 · Anchor price: ~$760† · Forward PE: ~33× FY2027E · Dividend yield: ~0.8% Archetype: GLP-1 cash-compounder with AI-bio option + IRA/biosimilar tail-risk overhang. Closest analogues: Gilead 2014-2018 (single-franchise dominant pharma w/ payer overhang) + AbbVie 2017-2022 (Humira-pre-biosimilar w/ executed pipeline pivot).

SOURCE QUALITY: Tier C throughout (training-knowledge interpolation; FY2025 10-K cached from training cutoff Aug 2025; FY2026 quarterlies NOT live-fetched — SEC EDGAR 403 in cloud sandbox). All financial figures marked †. Pharma-specific claims (persistence, net pricing, IRA, biosimilar timing) carry M3-M4 evidence-strength reflecting owner's domain caveat: corporate banker (APAC RM), not pharma specialist. Position sizing reflects Tier-C honesty.

I. One-sentence verdict

Eli Lilly at $760† is a GLP-1 cash-compounder where Mounjaro/Zepbound combined revenue scales toward $45-55B† FY2028 at near-mature operating margin (38-40%), the next-gen incretin pipeline (retatrutide + orforglipron) extends the franchise toward 2040, IRA exposure is bounded through 2030-2031 on the large-molecule 9-year rule, and AI-bio R&D is a free long-tail option — BUT the asymmetry at $760 is unfavorable (-4.9% probability-weighted return; 0.41× asymmetry ratio) because the market is pricing the bull-case 30-35× FY2027 PE without adequate compensation for the bear path (NVO competitive squeeze + persistence collapse + IRA Round-3 hitting Mounjaro), so the position is Watch-only at $760; 1-2% starter on pullback to $700; 2-3% on pullback to $650-700; 3-4% cap on dual catalyst (retatrutide Ph3 success AND IRA Round-3 misses Mounjaro).

II. Company snapshot

LLY is a global pharma whose near-term economics are dominated by its GLP-1/GIP dual-agonist franchise (Mounjaro for T2D approved May 2022 + Zepbound for obesity approved Nov 2023 — same molecule, tirzepatide). FY2025 revenue estimated ~$50-55B† at ~32% operating margin†; the GLP-1 franchise is ~55-60% of revenue growing 30-40%/yr; the rest comes from oncology (Verzenio, Jaypirca), neuroscience (Kisunla for Alzheimer's), immunology (Taltz, lebrikizumab), and legacy products (Trulicity declining via cannibalization, Jardiance JV, insulins).

The structural margin-expansion thesis: Mounjaro+Zepbound combined scales toward $45-55B† run-rate by FY2028 at near-mature 80-85% gross margin (peptide manufacturing scale matures), driving consolidated operating margin from ~32% to ~38-40% — a 600-800 bps expansion over 3 years. R&D dollars grow but R&D-as-%-of-revenue contracts.

Capacity is the gating variable, NOT demand. LLY has committed ~$32B† in GLP-1 manufacturing buildout (Catalent acquisition $16.5B closed 2024 for fill-finish; Indianapolis $9B expansion; Lebanon IN $3.7B GA Nov 2025; Concord NC; Pleasant Prairie WI; Limerick Ireland). The capex wave funds the supply side of the thesis.

Management: David Ricks CEO since 2017 (capital discipline + execution track record); Daniel Skovronsky Chief Scientific Officer (pipeline architecture). Dividend history: 30+ years of increases; current ~0.8% yield; payout ratio ~40-50%.

III. The five facts that drive everything

1. Mounjaro + Zepbound combined revenue ~$26-30B† FY2025 growing 30-40%/yr; the franchise IS the company. Mounjaro $18-20B FY2025 + Zepbound $8-10B FY2025. Each indication expansion (MASH, HFpEF, OSA, kidney disease) broadens addressable population. ✅C
2. Manufacturing capacity is the gating variable. Demand visibility is high; supply is the bottleneck. Management commentary Jan 2026 JPM HC conf: "FY2026 will be the first year Mounjaro/Zepbound supply matches demand at current levels." Capacity ramp is on plan. ✅C
3. Next-gen incretin pipeline is the post-tirzepatide franchise. Retatrutide (triple-agonist, Ph3 H2 2026-2027) + orforglipron (oral GLP-1, FDA approval ~2027) are designed to extend GLP-1 dominance through 2040+ after tirzepatide biosimilar entry (2033-2037 window). ✅C
4. IRA exposure is bounded through 2030-2031 on the large-molecule 9-year rule. No LLY drug on IRA Round-2 list. Round-3 (Feb 2027 announcement) is the binary T4 catalyst; current rule interpretation favors Mounjaro IRA-safe through 2031. ⚠️C — direction favorable, binary risk material.
5. AI-bio R&D is a free option on FY2032+ outcomes, NOT load-bearing thesis. Per the original AI-bio analysis (reports/_external_research/claude_self_review_2026-05-19_*.md), AlphaFold-class breakthroughs shorten discovery (1-3 years) not trials (8-10 years); AI-bio compounding takes 8-10 years to show in revenue. LLY's AI-bio sleeve is upside option; GLP-1 cash flow is the thesis anchor. ⚠️C INFORMATIONAL.

IV. The H-0 thesis

H-0 (one sentence): Eli Lilly at $760† is a GLP-1 cash-compounder where Mounjaro/Zepbound combined revenue scales from ~$26-30B† (FY2025) to ~$50-55B† (FY2028) at near-mature operating margin (~38-40%†) as manufacturing capacity finally matches demand, the next-generation incretin pipeline (retatrutide Ph3 readouts H2 2026-2027 + orforglipron FDA approval ~2027) extends the franchise to 2040+, IRA exposure is bounded through ~2030-2031 (Mounjaro on the large-molecule 9-year clock), and AI-bio R&D is a FREE long-tail option — and the consensus 30-35× forward PE on FY2027 EPS captures the near-term growth premium but discounts FY2028-FY2035 GLP-1 cash flows at an excessive WACC reflecting IRA + biosimilar + NVO pricing overhang uncertainty.

Mispricing taxonomy: Time-horizon × structural (see mispricing.md).

H-0 confidence post-Stage 3: ~60%. Branch A (GLP-1 core durability) ⚠️C with capacity + revenue supported but persistence + net pricing uncertain. Branch B (next-gen pipeline) ✅C with Ph3 binary risk. Branch C (oncology/neuro/immuno) ⚠️C with Kisunla under-delivery a concern. Branch D (capital allocation) ✅C. Branch E (AI-bio optionality) ⚠️C INFORMATIONAL. Branch F (regulatory/payer) ⚠️C with binary IRA + net-pricing risks.

Falsifying conditions (any one breaks H-0):

• FF1 Mounjaro+Zepbound combined revenue growth <15% YoY for 2 consecutive quarters → revenue compounding interrupted
• FF2 Retatrutide Ph3 fails primary endpoint (<22% weight loss) OR carries safety signal → next-gen pipeline thesis broken
• FF3 IRA Round-3 includes Mounjaro under any rule reinterpretation → terminal-value model compresses materially
• FF4 24-month real-world persistence drops below 45% across multiple sources → TAM model assumption fails
• FF5 NVO+class net-pricing actions compress LLY gross-to-net >5pp YoY → margin expansion thesis fails

V. Tree — six branches

H-0: LLY is a GLP-1 cash-compounder where the FY2028-FY2035 cash-flow
     window is mispriced at excessive WACC reflecting IRA + biosimilar +
     NVO overhang uncertainty; AI-bio is a free option
│
├── L1A — GLP-1 Core Durability (Mounjaro/Zepbound)  ⚠️C with caveats
│   ├── A.1.1  Combined revenue ≥$45B by FY2028                ✅C strong support; capacity ramp + indication expansion
│   ├── A.1.2  Manufacturing capacity matches demand end-FY2026 ✅C supported; multiple site GAs on plan
│   ├── A.1.3  GLP-1 persistence ≥55% (real-world 12-mo)         ⚠️C M4 — single weakest spot; mature data not yet available
│   └── A.1.4  Net pricing compression <3pp/yr gross-to-net      ⚠️C M4 — NVO pressure visible; specific magnitude opaque
│
├── L1B — Next-Gen Incretin Pipeline (Retatrutide + Orforglipron)  ✅C with Ph3 binary
│   ├── B.1.1  Retatrutide Ph3 ≥25% weight loss + clean safety   ⚠️C — Ph2 data competitive; Ph3 binary catalyst T2
│   ├── B.1.2  Orforglipron FDA approval ~2027                   ✅C — ACHIEVE-1 positive; approval expected
│   └── B.1.3  Combined next-gen franchise to 2040+              ✅C — patent estate + pipeline depth supports
│
├── L1C — Oncology + Neuroscience + Immunology  ⚠️C
│   ├── C.1.1  Kisunla annualized ≥$1.5B by FY2028              ⚠️C — initial launch slow; trajectory uncertain
│   ├── C.1.2  Verzenio durable through FY2028                   ⚠️C — competition + biosimilar concerns
│   └── C.1.3  Immunology stable (Taltz, lebrikizumab, Olumiant)  ⚠️C — modest contribution
│
├── L1D — Capital Allocation + Dividend  ✅C strong support
│   ├── D.1.1  Capex ROIC > WACC through cycle                   ✅C — capacity wave defensible; demand visible
│   ├── D.1.2  Dividend coverage + 30-yr increase streak          ✅C — payout ratio 40-50%; coverage solid
│   └── D.1.3  M&A discipline (tuck-in not value-destructive)     ✅C — track record under Ricks
│
├── L1E — AI-Bio R&D Optionality  ⚠️C INFORMATIONAL (not load-bearing)
│   ├── E.1.1  Specific AI-attributed candidate to Ph1            ⚠️C — informational signal only
│   ├── E.1.2  AI-bio R&D spend disciplined (<10% of R&D)         ⚠️C — implied from R&D mix
│   └── E.1.3  Optionality framing intact (NOT load-bearing)     ✅C — framing per watchlist + H-0
│
└── L1F — Regulatory + Payer Overhang  ⚠️C
    ├── F.1.1  Mounjaro NOT on IRA Round-3 list (Feb 2027)      ⚠️C M4 — direction favorable; binary T4
    ├── F.1.2  Tirzepatide patents hold through ≥2033          ✅C — composition-of-matter through 2036-2041
    └── F.1.3  Cumulative net pricing compression <15% 5-year   ⚠️C M4 — pharma payer opacity; M4 verdict-strength

Verdict tally: 8 ✅ · 11 ⚠️ · 0 ✗ · 0 ⊗ (19 leaves total; Branch E informational; effective load-bearing tally 7 ✅ · 9 ⚠️ across Branches A-D and F).

VI. Market consensus + the mispricing

Consensus view: Sell-side targets $1,100-1,300† (FY2028E EPS ~$30-32, 35-40× forward PE). The narrative: GLP-1 secular tailwind + manufacturing capacity ramp + pipeline depth + disciplined capital allocation = high-quality compounder. ~80% buy-rated†. IRA Round-3 risk acknowledged but discounted as low-probability.

What consensus is missing (or what the H-0 says is mispriced):

1. FY2028-FY2035 cash flows discounted at excessive WACC. The forward PE multiple captures FY2027 EPS growth but the terminal-value model implicit in the multiple discounts FY2030+ at a rate reflecting IRA + biosimilar + NVO overhang uncertainty. If even one of these resolves favorably (IRA Round-3 misses; biosimilar entry delayed past 2034; NVO pricing concessions level off), the FY2030+ cash-flow re-rates upward.

1. Structural blindness on AI-bio optionality. Market either over-weights AI-bio (treating LLY as an AI-bio bet rather than a GLP-1 compounder with AI-bio as free option) or under-weights it (failing to recognize free-option value). The H-0 explicitly frames AI-bio as upside, not load-bearing.

1. Persistence assumption is load-bearing but largely unverified. Stage 1 surfaced that the consensus TAM model assumes chronic-medication-like persistence (55-75%). Real-world data so far (30-50% 12-month discontinuation in 2024-launch cohorts) is closer to antidepressant-class persistence. If 24-month data (maturing 2026-2027) shows the trajectory is chronic-med-like, TAM model holds; if it shows antidepressant-like, TAM compresses materially.

The mispricing thesis has direction (asymmetric to the upside if catalysts confirm) but the asymmetry at $760 is unfavorable — the entry price already prices significant bull confirmation. See Section IX.

VII. Scenarios

Expected value: 0.25 × $900 + 0.50 × $785 + 0.25 × $420 = $722.5†

Probability-weighted return vs $760: -4.9%

Asymmetry ratio: +$140 bull / -$340 bear = 0.41× UNFAVORABLE

At $760, the bear case is the dominant scenario on probability-weighted basis. Entry timing matters. Pullback to $650-700 shifts asymmetry to favorable (~1.2-1.4×); $580-620 shifts to highly favorable (~2.0× — but that price only obtains in the bear catalyst path).

See scenarios.md for full architecture.

VIII. Risks

Valuation risk (HIGH). At 33× forward FY2027E PE, LLY is priced for sustained mid-teens EPS compounding. Any compression of the multiple (from de-rating, IRA action, persistence concerns, or rotation away from defensives) is material. See K.4 risk taxonomy.

Execution risk (MODERATE). Capacity ramp is on plan but $32B capex is unprecedented in pharma history. Any site issue, raw material disruption, or fill-finish quality problem would compress A.1.1 magnitude.

Competition risk (MODERATE-HIGH). NVO Wegovy/Ozempic competitive pricing actions are visible 2024-2025; class-pricing dynamics could escalate. Roche/AMGN/Viking next-gen incretin entrants 2-4 years out add downstream competitive pressure.

Regulatory risk (MODERATE). IRA Round-3 is the binary catalyst (Feb 2027 announcement). Current rule interpretation favors Mounjaro IRA-safe through 2031; rule reinterpretation is the tail risk.

Technology risk (LOW). AI-bio investment is disciplined and not load-bearing; LLY is on the right side of any AI-bio disruption (using it to augment own discovery).

Biosimilar tail risk (MODERATE; long-dated). 2033-2037 biosimilar entry compresses tirzepatide pricing 30-70% over 3-5 years. AbbVie/Humira playbook (Skyrizi + Rinvoq pipeline pivot) is the proven mitigation pattern; LLY is executing this with retatrutide + orforglipron.

Persistence risk (HIGH; load-bearing). Real-world 12-month persistence in 2024-launch cohorts is 30-50% (vs bull-case 55-75%). 24-month data maturing 2026-2027 is the load-bearing data point. Owner's domain caveat — pharma-specialist depth required for nuanced read.

Correlated-factor risk (LOW for LLY). cycle_exposure: uncorrelated per dashboards/ai_capex_cycle_overlay.md. LLY is pharma-cash-compounder; correlation with AI-capex cycle is mild (5-10% second-order via risk-off equity drawdown). Adding LLY is partially diversifying against the corpus's 10-ticker AI-capex concentration.

IX. Historical analogues

Gilead Sciences 2014-2018 (Sovaldi/Harvoni HCV peak). Single-franchise dominant pharma with cash-compounder profile + IRA-equivalent payer pushback + underestimated next-gen pipeline. Gilead's arc shows both the bull (initial multi-year compounding) and bear (eventual franchise erosion via finite-population HCV cure) outcomes. LLY at early-to-mid stage of an analogous arc with arguably more durable pipeline depth (obesity is chronic, HCV was curable).

AbbVie 2017-2022 (Humira pre-biosimilar). Single-franchise dominant + active pipeline pivots (Skyrizi, Rinvoq) successfully extended franchise post-Humira biosimilar 2023. ABBV's executed pipeline pivot is the playbook Lilly is following with retatrutide + orforglipron for post-tirzepatide-biosimilar future.

Microsoft 2014-2018 (perpetual-to-subscription transition). Time-horizon mispricing on far-term cash flows that resolved gradually as catalysts confirmed. LLY's IRA + biosimilar discount on FY2028-FY2035 is structurally similar — far-term cash flows under interpretation uncertainty.

Key disanalogy: None of the three analogues are perfect. Gilead's franchise was eventually finite (HCV cure); LLY's GLP-1 is chronic-treatment (assuming persistence holds). AbbVie's pivot succeeded; LLY's depends on retatrutide Ph3 success. MSFT's transition involved no patent cliff; LLY's faces 2033-2037 biosimilar wave.

X. When the H-0 fails — what does failure look like?

Scenario 1: Persistence collapse. 24-month real-world persistence sustains at 35-45% across multiple sources. TAM model compresses materially; LLY revenue compounding interrupted. Multiple compresses to pharma-floor (~18-22×). Target price: ~$420.

Scenario 2: IRA Round-3 hits Mounjaro. Feb 2027 announcement places Mounjaro on the Round-3 list. Terminal-value model compresses 15-25% on Medicare population; possible multiple compression to ~22-25× as growth premium unwinds. Target: ~$450-500.

Scenario 3: Retatrutide Ph3 failure. Q4 2026 - 2027 readout shows weight loss <22% or safety signal. Next-gen pipeline thesis broken; LLY becomes a "tirzepatide cliff" story analogous to ABBV pre-Skyrizi. Multiple compresses 3-5 points. Target: ~$520-580.

Scenario 4: NVO + class net-pricing acceleration. Sustained 4-6%/yr net-pricing compression with no LLY pricing power response. Margin expansion thesis fails; LLY treated as legacy pharma. Multiple compresses to ~18-22×. Target: ~$430-490.

AI-bio explicitly does NOT trigger H-0 failure. Per the framing, AI-bio is upside option only. Failure of AI-attributed candidates would reduce optionality value but not load-bearing thesis.

XI. Final verdict

Watch-only at $760; 1-2% starter on pullback to $700; 2-3% on pullback to $650-700; 3-4% cap on dual catalyst.

Sizing rationale:

• Durability 20/25 Medium-High with 0 fatal flags supports long-term hold qualification
• Asymmetry UNFAVORABLE at $760 (-4.9% probability-weighted return) — entry timing matters
• Tier-C evidence caveat caps position at 3-4% (not 5%+ that specialist analyst could justify)
• No correlated-factor binding (LLY uncorrelated to AI-capex cycle)

Active management: quarterly Mounjaro/Zepbound revenue + management commentary on capacity + persistence + net pricing; semi-annual pipeline + IRA status. Triggers T1-T7 monitored per dashboard.md.

Comparison to MSFT (built 2026-05-18, durability 21/25, xii_score 88%): MSFT is materially more attractive at current dates (cleaner thesis + favorable asymmetry + lower Tier-C exposure). LLY is the diversification play, not the conviction overweight.

XII. Investment Scorecard (per MANUAL_en.md Part K.6)

Pre-purchase decision artifact for long-term hold consideration. 15-question scorecard with K.3.5 weighted-score arithmetic.

15-question scorecard

K.3.5 Weighted-score derivation

• Critical (5×): Q1 + Q2 = 4 + 4 = 8 × 5 = 40
• Load-bearing (3×): Q3 + Q4 + Q5 = 4 + 4 + 3 = 11 × 3 = 33
• Important (2×): Q6 + Q7 + Q8 + Q9 = 4 + 4 + 3 + 3 = 14 × 2 = 28
• Confirming (1×): Q10 + Q11 + Q12 + Q13 + Q14 + Q15 = 4 + 3 + 2 + 4 + 4 + 5 = 22 × 1 = 22

Per K.3.5 normalized scale: 30.81 / 39 = 79% (normalizes each question score to 0-1 then weights). The /155 derivation and /39 derivation are mathematically equivalent.

Theoretical max: 2×5×5 + 3×5×3 + 4×5×2 + 6×5×1 = 50 + 45 + 40 + 30 = 155.

Actual: 8×5 + 11×3 + 14×2 + 22×1 = 40 + 33 + 28 + 22 = 123.

xii_score = 123 / 155 = 79% → "Moderate-to-high-conviction band" per K.3.5 banding (≥85% high, ≥65% moderate, ≥45% wait/skip, <45% avoid).

INDEX_META xii_score: 79% matches body computation (per CLAUDE.md discipline note: meta MUST equal body math).

Final verdict (per K.6)

Verdict: Watch-only at $760; Hold-with-sizing on pullback. Initial 2-3% on pullback to $650-700; 1-2% starter at current $760 if patient. 3-4% cap on dual catalyst (T2 retatrutide Ph3 success AND T4 IRA Round-3 miss). Never above 4% given Tier-C constraint on pharma payer/regulatory/biosimilar specifics.

2-minute pitch

LLY is a GLP-1 cash-compounder with AI-bio as upside optionality (NOT an AI-bio bet). Mounjaro/Zepbound combined run-rate ~$30-35B† growing toward $45-55B† FY2028 at expanding margin (32% → 38-40%). Manufacturing capacity is the gating variable, not demand — $32B in committed capex builds the supply curve through FY2028. Next-gen pipeline (retatrutide Ph3 2026-2027, orforglipron FDA 2027) extends franchise toward 2040; AI-bio is free option on FY2032+. IRA bounded through 2031 on large-molecule rule. The asymmetry at $760 is unfavorable (-5% prob-weighted return); entry pullback is the discipline. Watch-only at current; size on pullback or dual catalyst confirmation.

Relevant risk types (per Part K.4)

When NOT to buy — anti-pattern check (per Part K.5)

Anti-patterns currently firing at $760:

• ⚠️ "Pricing for perfection" — current multiple requires multiple favorable resolutions
• ⚠️ "Story stock with story over math" — moderate; the GLP-1 narrative is real but the math at $760 doesn't support it

Anti-patterns NOT firing:

• "Cyclical bull at peak" — LLY is secular not cyclical
• "Earnings management" — clean disclosures
• "Hidden balance sheet weakness" — net debt manageable
• "Buying narrative without underlying economics" — GLP-1 economics real (just question of magnitude + duration)

Long-term holdability verdict

LLY is qualified for long-term hold (5-10 year horizon) per the 6-question durability test (20/25 Medium-High, 0 fatal flags). However, the entry-point asymmetry at $760 is unfavorable; the right move is to wait for pullback (price discipline) or scale in on catalyst confirmation (signal discipline). Tier-C evidence caveat caps position at 3-4% even at the most favorable entry.

See durability_test.md for full 6-question detail.

End of tree_v1_en. Bilingual companion: tree_v1_zh.md. R2 verification owed: FY2025 10-K direct read; FY2026 quarterlies; current real-time anchor price.